 |
Disease
Areas of Focus

Compounds
and research programs in Discovery are at the earliest stages
of research. Compounds in Exploratory Development are in
preclinical or early clinical development. Full development compounds
are investigational drugs that are in late-stage clinical development,
have been submitted to regulatory agencies for approval, or have
been approved in one major market and are pending approval
in other major markets. Lifecycle Management products are among
approved medicines that
are driving
current and future growth while continuing their clinical development
to determine whether additional indications and formulations will
benefit patients.
Like
any other scientific endeavor, clinical testing of novel drug
compounds is a complex time-consuming, resource-intensive
process
with no guaranteed results. But, as described here, Bristol-Myers
Squibb is committed to pursuing such clinical development and,
in doing so, to bringing new hope to patients. |